Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2010
07/01/2010US20100166860 Medicine for treating gastrointestinal disorder including acquired lactose-intolerance irritable bowel syndrome
07/01/2010US20100166857 Pharmaceutical dosage forms and methods of manufacturing same
07/01/2010US20100166856 Pharmaceutical composition in the form of coated microspheres for the modified release of a muscle relaxant and an nsaid
07/01/2010US20100166853 Coated preparation
07/01/2010US20100166852 Cream gels comprising at least one retinoid and benzoyl peroxide
07/01/2010US20100166851 Composition having lipolytic activity, production method thereof and use of the composition
07/01/2010US20100166850 Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
07/01/2010US20100166849 Glutathione based delivery system
07/01/2010US20100166848 Liposomal formulations for treating cancer
07/01/2010US20100166847 Method for coating fine particles with lipid membrane
07/01/2010US20100166845 Individualized cancer therapy
07/01/2010US20100166843 Pharmaceutical composition comprising a campothecin derivative
07/01/2010US20100166839 Non peptidic renin inhibitors nitroderivatives
07/01/2010US20100166838 Methods And Compositions For Modulating Keratinocyte Function
07/01/2010US20100166837 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation
07/01/2010US20100166836 Transdermal Therapeutic System for Volatile and/or Thermo-Labile Substances
07/01/2010US20100166833 Compositions, articles and methods for preventing or reducing tobacco-associated damage
07/01/2010US20100166831 Microencapsulated Nucleotide Formulations for Aquaculture and Land Animal Feeds
07/01/2010US20100166826 Biodegradable intravaginal devices for delivery of therapeutics
07/01/2010US20100166825 Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
07/01/2010US20100166819 Transforming Growth Factor Modulators
07/01/2010US20100166811 Gras composition for intranasal delivery of parathyroid hormone
07/01/2010US20100166810 Combination tablet with chewable outer layer
07/01/2010US20100166808 Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
07/01/2010US20100166806 Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency
07/01/2010US20100166805 Modulation of immunostimulatory properties by small oligonucleotide-based compounds
07/01/2010US20100166804 Methods
07/01/2010US20100166799 Adenoviral vectors and methods and uses related thereto
07/01/2010US20100166798 Method and kit for treatment/prevention of hair loss
07/01/2010US20100166787 Vaccines and methods for using the same
07/01/2010US20100166786 A mycobacterium tuberculosis fusion protein and uses thereof
07/01/2010US20100166781 Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
07/01/2010US20100166780 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity
07/01/2010US20100166776 Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
07/01/2010US20100166771 detecting NTHi bacteria in a biological sample using a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 599; vaccines and methods of treating and preventing NTHi related disorders such as NTHi infection of the middle ear and/or the nasopharynx
07/01/2010US20100166770 Antagonists of bacterial sequences
07/01/2010US20100166765 Benzoquinazoline derivatives
07/01/2010US20100166747 Methods and compositions for treating tumor diseases
07/01/2010US20100166739 Methods and Compositions for Diagnosing Urological Disorders
07/01/2010US20100166738 Compositions and methods for wt1 specific immunotherapy
07/01/2010US20100166737 P38Alpha as a Therapeutic Target in Bladder Carcinoma
07/01/2010US20100166736 Immunostimulatory oligonucleotide multimers
07/01/2010US20100166735 Methods and compositions for reduction of side effects of therapeutic treatments
07/01/2010US20100166733 Mcp-1 splice variants and methods of using same
07/01/2010US20100166732 Small streptococcus pyogenes antigens and their use
07/01/2010US20100166731 Methods and Compositions for Treating Cancer
07/01/2010US20100166727 S-Adenosylmethionine And Methylthioadensosine In Chemoprevention And Treatment Of Colon Polyps And Cancer
07/01/2010US20100166726 Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
07/01/2010US20100166710 Compositions and Methods for Inducing Neuronal Differentiation
07/01/2010US20100166707 Extracellular matrix/metastasis modifier genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
07/01/2010US20100166706 Hcv ns-3 serine protease inhibitors
07/01/2010US20100166704 Methods and compositions for inhibition of viral replication
07/01/2010US20100166703 Use of il-6/il-6 chimera in huntington's disease
07/01/2010US20100166701 Method for treating renal cell carcinoma using glycogenolysis inhibitors
07/01/2010US20100166699 Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
07/01/2010US20100166698 New compositions and methods for the treatment of inflammation
07/01/2010US20100166696 Amido-amine dendrimer compositions
07/01/2010US20100166695 Multivalent Heterobifunctional Polymers And Methods Of Their Use
07/01/2010US20100166694 Diagnostic markers of wound infection
07/01/2010US20100166681 Anhydrous Multiphase Gel System
07/01/2010US20100166676 RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
07/01/2010US20100166675 Pharmaceutical Composition for the Treatment of Type 1-Diabetes
07/01/2010US20100166674 Transdermal delivery rate control using amorphous pharmaceutical compositions
07/01/2010US20100166672 Foam-forming composition
07/01/2010US20100166671 Organic compounds
07/01/2010US20100166670 Use of boswellic acid and its derivatives for inhibiting normal and increased leucocytic elastase or plasmin activity
07/01/2010US20100166661 siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION
07/01/2010US20100166656 Diagnostic And Radiotherapeutic Contrast Agents And Process For Their Preparation
07/01/2010US20100166655 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
07/01/2010US20100163032 Nasal formulations of metoclopramide
07/01/2010DE102008063667A1 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate 3- (3-pyrimidin-2-yl-benzyl) - ° [1,2,4] triazolo [4,3-b] pyrimidine derivatives
07/01/2010DE102008062826A1 Pyridazinonderivate Pyridazinone derivatives
07/01/2010DE102006024834B4 Neue Indol-Pyrrol-Derivate und deren Verwendungen New indole-pyrrole derivatives and their uses
07/01/2010CA2780485A1 Nasal formulations of metoclopramide
07/01/2010CA2772760A1 Small molecule inhibitors of necroptosis
07/01/2010CA2750891A1 Compositions comprising decitabine and tetrahydrouridine and uses thereof
07/01/2010CA2750841A1 Pyrimidine indole derivatives for treating cancer
07/01/2010CA2750371A1 Dry powder pharmaceutical composition for inhalation
07/01/2010CA2748397A1 1, 2, 4 -oxadiazole derivatives and their therapeutic use
07/01/2010CA2748339A1 Plant extracts from acronychia species and their use
07/01/2010CA2748296A1 Implantable composites and compositions comprising releasable bioactive agents
07/01/2010CA2748294A1 Piperidine derivatives useful as orexin antagonists
07/01/2010CA2748289A1 Preparation method of dihydroindene amide compounds,their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor
07/01/2010CA2748268A1 Compositions for drug administration
07/01/2010CA2748251A1 Novel bicyclic heterocyclic compound
07/01/2010CA2748250A1 Indanyl compounds
07/01/2010CA2748249A1 Cyclic amine compounds
07/01/2010CA2748235A1 Ethanamine compounds and their use for treating depression
07/01/2010CA2748218A1 Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
07/01/2010CA2748163A1 Agents for treating spinal canal stenosis
07/01/2010CA2748159A1 Selective histamine h4 receptor antagonists for the treatment of vestibular disorders
07/01/2010CA2748124A1 Ppar agonist compositions and methods of use
07/01/2010CA2748105A1 Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one as agonist of the .beta.2 adrenergic receptor
07/01/2010CA2748103A1 Liquid pharmaceutical compositions comprising a triptan compound and xylitol
07/01/2010CA2748100A1 Alkaloid aminoester derivatives and medicinal composition thereof
07/01/2010CA2748099A1 7-phenoxychroman carboxylic acid derivatives
07/01/2010CA2748057A1 Nucleoside phosphoramidates
07/01/2010CA2748038A1 Method for inducing a trif-bias
07/01/2010CA2748016A1 Synthesis of purine nucleosides
07/01/2010CA2747998A1 Safe desmopressin administration
1 ... 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 ... 7860